Terms: = Thyroid cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Treatment
61 results:
1. thyroid dysfunction caused by exposure to environmental endocrine disruptors and the underlying mechanism: A review.
He J; Xu J; Zheng M; Pan K; Yang L; Ma L; Wang C; Yu J
Chem Biol Interact; 2024 Mar; 391():110909. PubMed ID: 38340975
[TBL] [Abstract] [Full Text] [Related]
2. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
3. Fine-needle biopsy of thyroid nodules and the contribution of molecular analysis of BRAF and RAS mutations.
Kasko M; Grigerova M; Alemayehu A; Zavodna K; Kasko V; Podoba J
Bratisl Lek Listy; 2023; 124(12):869-872. PubMed ID: 37983279
[TBL] [Abstract] [Full Text] [Related]
4. Macrofollicular Architecture in Invasive Encapsulated Follicular Variant of Papillary thyroid Carcinoma: A Pitfall in thyroid Practice.
Yadav S; Kandasamy D; Damle N; Goel R; Chumber S; Sharma MC; Boruah M; Agarwal S
Head Neck Pathol; 2023 Dec; 17(4):899-909. PubMed ID: 37775618
[TBL] [Abstract] [Full Text] [Related]
5.
Alamri AM; Alkhilaiwi FA; Khan NU; Tasleem M
Anticancer Agents Med Chem; 2023; 23(19):2111-2126. PubMed ID: 37287303
[TBL] [Abstract] [Full Text] [Related]
6. Identification of crucial genes involved in thyroid cancer development.
Kalarani IB; Sivamani G; Veerabathiran R
J Egypt Natl Canc Inst; 2023 May; 35(1):15. PubMed ID: 37211566
[TBL] [Abstract] [Full Text] [Related]
7. Tumor-Infiltrating Immune Cell Landscapes in the Lymph Node Metastasis of Papillary thyroid cancer.
Amanullah M; Pan M; Lu K; Pan X; Lu Y; Luo D; Liu P
Curr Oncol; 2023 Feb; 30(3):2625-2641. PubMed ID: 36975413
[TBL] [Abstract] [Full Text] [Related]
8. Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors.
Garcia-Rendueles MER; Krishnamoorthy G; Saqcena M; Acuña-Ruiz A; Revilla G; de Stanchina E; Knauf JA; Lester R; Xu B; Ghossein RA; Fagin JA
Mol Cancer; 2022 Dec; 21(1):213. PubMed ID: 36476495
[TBL] [Abstract] [Full Text] [Related]
9. Clinicopathological and Molecular Features of Secondary cancer (Metastasis) to the thyroid and Advances in Management.
Nguyen M; He G; Lam AK
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328664
[TBL] [Abstract] [Full Text] [Related]
10. Response to immunotherapy in a patient with anaplastic thyroid cancer: A case report.
Zheng L; Li L; He Q; Wang M; Ma Y; Zhu J; Li Y; Fu X; Zhang Y
Medicine (Baltimore); 2021 Aug; 100(32):e26138. PubMed ID: 34397868
[TBL] [Abstract] [Full Text] [Related]
11. Total thyroidectomy can still remain the method of choice in some Bethesda III cases.
Lukas J; Hintnausova B; Sykorova V; Syrucek M; Maly M; Duskova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Mar; 167(1):61-68. PubMed ID: 34282807
[TBL] [Abstract] [Full Text] [Related]
12. A Narrative Review of Genetic Alterations in Primary thyroid Epithelial cancer.
Romei C; Elisei R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572167
[TBL] [Abstract] [Full Text] [Related]
13. The Integrated Analyses of Driver Genes Identify Key Biomarkers in thyroid cancer.
Xu Q; Song A; Xie Q
Technol Cancer Res Treat; 2020; 19():1533033820940440. PubMed ID: 32812852
[TBL] [Abstract] [Full Text] [Related]
14. Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.
Desai J; Gan H; Barrow C; Jameson M; Atkinson V; Haydon A; Millward M; Begbie S; Brown M; Markman B; Patterson W; Hill A; Horvath L; Nagrial A; Richardson G; Jackson C; Friedlander M; Parente P; Tran B; Wang L; Chen Y; Tang Z; Huang W; Wu J; Zeng D; Luo L; Solomon B
J Clin Oncol; 2020 Jul; 38(19):2140-2150. PubMed ID: 32182156
[TBL] [Abstract] [Full Text] [Related]
15. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro.
Ullmann TM; Liang H; Moore MD; Al-Jamed I; Gray KD; Limberg J; Stefanova D; Buicko JL; Finnerty B; Beninato T; Zarnegar R; Min IM; Fahey TJ
Surgery; 2020 Jan; 167(1):56-63. PubMed ID: 31585718
[TBL] [Abstract] [Full Text] [Related]
16. Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated thyroid cancer: Subanalysis of the Sorafenib Phase III DECISION Trial.
Brose MS; Schlumbeger M; Jeffers M; Kappeler C; Meinhardt G; Peña CEA
Clin Cancer Res; 2019 Dec; 25(24):7370-7380. PubMed ID: 31558473
[TBL] [Abstract] [Full Text] [Related]
17. Impact of ultrasonographic features, cytomorphology and mutational testing on malignant and indeterminate thyroid nodules on diagnostic accuracy of fine needle cytology samples: A prospective analysis of 141 patients.
Fulciniti F; Cipolletta Campanile A; Malzone MG; Chiofalo MG; Capiluongo A; Monaco M; Di Maio N; Sandomenico F; Botti G; Chiappetta G; Vuttariello E; Pezzullo L
Clin Endocrinol (Oxf); 2019 Dec; 91(6):851-859. PubMed ID: 31483883
[TBL] [Abstract] [Full Text] [Related]
18. Exogenous Hydrogen Sulfide Regulates the Growth of Human thyroid Carcinoma Cells.
Wu D; Li J; Zhang Q; Tian W; Zhong P; Liu Z; Wang H; Wang H; Ji A; Li Y
Oxid Med Cell Longev; 2019; 2019():6927298. PubMed ID: 31223424
[TBL] [Abstract] [Full Text] [Related]
19. EAA clinical practice guidelines-gynecomastia evaluation and management.
Kanakis GA; Nordkap L; Bang AK; Calogero AE; Bártfai G; Corona G; Forti G; Toppari J; Goulis DG; Jørgensen N
Andrology; 2019 Nov; 7(6):778-793. PubMed ID: 31099174
[TBL] [Abstract] [Full Text] [Related]
20. Clinical impact of testing for mutations and microRNAs in thyroid nodules.
Sistrunk JW; Shifrin A; Frager M; Bardales RH; Thomas J; Fishman N; Goldberg P; Guttler R; Grant E
Diagn Cytopathol; 2019 Aug; 47(8):758-764. PubMed ID: 31013001
[TBL] [Abstract] [Full Text] [Related]
[Next]
